Cuprina Reaffirms Commitment to Shareholders and Patients Following Recent Stock Market Activity
Cuprina Holdings (NASDAQ:CUPR) has issued a statement addressing recent unusual trading volatility in its stock. The company emphasized that it remains fully operational and legally compliant, with no known operational reasons or material adverse events causing the stock fluctuations.
CEO David Quek confirmed that no initial shareholders or founding team members have sold their stock in the past week. The company is progressing with key milestones, including FDA clearance submission for medical maggot therapy, expansion into the GCC region, and exploring potential joint ventures in chronic wound management.
Cuprina, which completed its IPO earlier this year, maintains its commitment to transparency and execution of its business plan while focusing on advancing its biotherapeutic pipeline.
Cuprina Holdings (NASDAQ:CUPR) ha pubblicato una nota relativa alla recente volatilit脿 anomala delle azioni. La societ脿 ha sottolineato di essere pienamente operativa e conforme alle normative, senza evidenza di cause operative o eventi negativi rilevanti che possano spiegare le oscillazioni del titolo.
Il CEO David Quek ha confermato che nei giorni scorsi n茅 azionisti iniziali n茅 membri del team fondatore hanno venduto le proprie azioni. L鈥檃zienda procede con le tappe previste, tra cui la presentazione per l鈥檃utorizzazione FDA della terapia con larve mediche, l鈥檈spansione nel Gulf Cooperation Council (GCC) e la valutazione di joint venture nel campo della gestione delle ferite croniche.
Cuprina, che ha completato l鈥橧PO all鈥檌nizio di quest鈥檃nno, ribadisce l鈥檌mpegno alla trasparenza e all鈥檈secuzione del piano industriale, continuando a puntare sullo sviluppo della sua pipeline bioterapeutica.
Cuprina Holdings (NASDAQ:CUPR) emiti贸 un comunicado sobre la reciente volatilidad inusual en la cotizaci贸n de sus acciones. La compa帽铆a afirm贸 que se mantiene totalmente operativa y en cumplimiento legal, sin identificar razones operativas ni eventos adversos materiales que expliquen las fluctuaciones.
El CEO David Quek confirm贸 que ning煤n accionista inicial ni miembro del equipo fundador ha vendido acciones en la 煤ltima semana. La empresa avanza en hitos clave, incluida la presentaci贸n para la aprobaci贸n de la FDA de la terapia con larvas m茅dicas, la expansi贸n en la regi贸n del GCC y la exploraci贸n de posibles joint ventures en el manejo de heridas cr贸nicas.
Cuprina, que complet贸 su oferta p煤blica inicial a principios de este a帽o, mantiene su compromiso con la transparencia y la ejecuci贸n de su plan de negocio, enfoc谩ndose en el avance de su cartera bioterap茅utica.
Cuprina Holdings (NASDAQ:CUPR)電� 斓滉芳 欤缄皜鞚� 鞚措鞝� 氤�霃欖劚鞐� 雽�頃� 靹彪獏鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞕勳爠 臧�霃� 欷戩澊氅� 氩曣窚毳� 欷�靾橅晿瓿� 鞛堧嫟瓿� 臧曥“頄堨溂氅�, 欤缄皜 氤�霃欖潉 靹る獏頃� 鞖挫榿靸� 鞚挫湢雮� 欷戩殧頃� 攵堧Μ頃� 靷贝鞚� 頇曥澑霅橃 鞎婌晿鞀惦媹雼�.
CEO David Quek電� 齑堦赴 欤检＜雮� 彀届梾 氅る矂臧� 歆�雮� 欤检棎 欤检嫕鞚� 毵る弰頃橃 鞎婌晿雼�瓿� 頇曥澑頄堨姷雼堧嫟. 須岇偓電� 鞚橂鞖� 甑崝旮� 旃橂鞐� 雽�頃� FDA 鞀轨澑 鞁犾箔鞚� 韽暔頃� 欤检殧 毵堨澕鞀ろ啢鞚� 歆勴枆 欷戩澊氅�, GCC 歆�鞐溂搿滌潣 頇曥灔瓿� 毵岇劚 靸侅矘 甏�毽� 攵勳暭鞐愳劀鞚� 頃╈瀾 韴瀽 臧�電レ劚霃� 氇儔頃橁碃 鞛堨姷雼堧嫟.
鞓暣 齑� IPO毳� 鞕勲頃� Cuprina電� 韴獏靹标臣 靷梾瓿勴殟 鞁ろ枆鞐� 雽�頃� 鞚橃毳� 鞙犾頃橂┌ 靸濍旃橂鞝� 韺岇澊頂勲澕鞚胳潣 歆勳爠鞐� 欤茧牓頃橁碃 鞛堨姷雼堧嫟.
Cuprina Holdings (NASDAQ:CUPR) a publi茅 une d茅claration concernant la r茅cente volatilit茅 inhabituelle de son titre. La soci茅t茅 a soulign茅 qu鈥檈lle demeure enti猫rement op茅rationnelle et en conformit茅 l茅gale, sans raisons op茅rationnelles connues ni 茅v茅nements d茅favorables significatifs expliquant ces fluctuations.
Le PDG David Quek a confirm茅 que aucun actionnaire initial ni membre de l鈥櫭﹒uipe fondatrice n鈥檃 vendu d鈥檃ctions au cours de la semaine pass茅e. L鈥檈ntreprise progresse sur des jalons cl茅s, notamment la d茅p么t pour l鈥檃utorisation FDA de la th茅rapie par larves m茅dicales, l鈥檈xpansion dans la r茅gion du CCG et l鈥檈xploration de coentreprises potentielles pour la prise en charge des plaies chroniques.
Cuprina, qui a finalis茅 son IPO au d茅but de cette ann茅e, r茅affirme son engagement en faveur de la transparence et de l鈥檈x茅cution de son plan d鈥檃ffaires, tout en se concentrant sur l鈥檃vancement de sa pipeline bioth茅rapeutique.
Cuprina Holdings (NASDAQ:CUPR) hat eine Stellungnahme zur j眉ngsten ungew枚hnlichen Handelsvolatilit盲t seiner Aktie ver枚ffentlicht. Das Unternehmen betonte, dass es voll einsatzf盲hig und rechtlich compliant sei und keine bekannten operativen Gr眉nde oder wesentlichen negativen Ereignisse vorl盲gen, die die Kursschwankungen erkl盲ren k枚nnten.
CEO David Quek best盲tigte, dass weder fr眉he Aktion盲re noch Gr眉ndungsmitglieder in der vergangenen Woche Aktien verkauft haben. Das Unternehmen macht Fortschritte bei wichtigen Meilensteinen, darunter die Einreichung zur FDA-Freigabe der medizinischen Maden-Therapie, die Expansion in die GCC-Region und die Pr眉fung m枚glicher Joint Ventures im Bereich der Behandlung chronischer Wunden.
Cuprina, das Anfang dieses Jahres seinen B枚rsengang abgeschlossen hat, bekr盲ftigt sein Engagement f眉r Transparenz und die Umsetzung des Gesch盲ftsplans und konzentriert sich auf die Weiterentwicklung seiner biotherapeutischen Pipeline.
- No stock sales by initial shareholders or founding team members, showing confidence in company
- FDA clearance submission for medical maggot therapy in progress
- Geographic expansion into GCC region underway
- Actively exploring M&A opportunities in wound management
- Unusual stock trading volatility raising investor concerns
- Recent IPO company still establishing market presence
Insights
Cuprina's response to unusual trading volatility offers reassurance but lacks specific financial details to fully address investor concerns.
Cuprina's public statement addressing recent stock volatility represents a classic corporate response to market uncertainty. The company is taking a defensive posture by emphasizing three key points: operational stability, insider stock retention, and ongoing business execution. However, the statement is notably light on quantitative information.
The lack of specific financial metrics or performance indicators is significant. While management asserts the company is in a "healthy position," they provide no concrete financial data to substantiate this claim. This communication strategy focuses on qualitative reassurance rather than quantitative proof.
Most revealing is the company's explicit statement that it has no knowledge of material adverse events that could explain the stock volatility. This carries regulatory significance as public companies must disclose material information. The retention of shares by founding team members and initial shareholders suggests internal confidence, though without disclosure of exact ownership percentages or lockup details.
The pipeline updates regarding FDA clearance applications, GCC regional expansion, and M&A exploration reaffirm previously communicated strategic directions rather than announcing new developments. These represent continuity of existing plans rather than new catalysts.
This statement appears designed primarily to stabilize market perception during a period of unexplained volatility, functioning more as reputation management than material financial disclosure. For investors, the reassurance of operational continuity must be weighed against the absence of updated financial performance metrics.
Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (鈥�Cuprina鈥� or 鈥�the Company鈥�) issued the following statement in response to recent unusual trading activity and speculation surrounding the Company.
Over the past week, the Company鈥檚 stock has experienced heightened trading volatility, which we understand has raised concerns among some shareholders. We want to take this opportunity to reaffirm that Cuprina is a fully operational, legally compliant, and mission-driven biotechnology company. We remain focused on advancing our pipeline, expanding access to our biotherapeutic solutions, and delivering long-term value to patients, clinicians, and shareholders alike.
鈥淲e recognize that some investors have questions following Friday鈥檚 unusual trading activity. The Company is not aware of any operational reasons for this stock price volatility nor of any material adverse events which may have led to this activity. Let us be clear: Cuprina is operationally in a healthy position and is diligently executing on its business plan since the Company鈥檚 Initial Public Offering earlier this year. We are a Nasdaq-listed company with audited financials, an expanding footprint in Asia and beyond, and a pipeline of regulated medical products serving and benefitting real patients in need. Our team continues to work tirelessly to commercialize breakthrough biologics and scale our global partnerships. While share price volatility is largely outside of our control, execution and transparency remain firmly within it,鈥� said David Quek, Chief Executive Officer and Executive Director of Cuprina.
The Company also emphasizes that, to its knowledge, none of the Company鈥檚 initial shareholders or founding team members have sold their stock over the past week. This underscores our collective confidence in the Company鈥檚 mission, strategy, and long-term growth聽potential.
The Company remains on track with its operational and regulatory milestones, including:
聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 鈥⒙犅犅犅犅犅犅犅犅犅犅犅� Submission of FDA clearance for its medical maggot therapy;
聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 鈥⒙犅犅犅犅犅犅犅犅犅犅犅� Expansion of maggot distribution to the Gulf Cooperation Council (GCC) region;
聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 鈥⒙犅犅犅犅犅犅犅犅犅犅犅� Exploring potential joint ventures and mergers & acquisitions to build a continuum of care in chronic wound management products.
Cuprina will continue to keep shareholders updated on key developments and milestones through timely disclosures and filings. We deeply value the trust and support of our shareholders and are committed to communicating with transparency and integrity, and delivering on our business and market share growth as communicated to our valued shareholders.
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit .听听
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: [email protected]
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email:
FAQ
What caused the recent stock volatility in Cuprina (NASDAQ:CUPR) shares?
Have any Cuprina (CUPR) insiders sold shares during the recent volatility?
What are Cuprina's (CUPR) main business milestones for 2025?
When did Cuprina (CUPR) complete its IPO?
What is Cuprina's (CUPR) main business focus?
